These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21468954)

  • 1. A protocol for the preparation of cryoprecipitate and cryodepleted plasma.
    Sparrow RL; Greening DW; Simpson RJ
    Methods Mol Biol; 2011; 728():259-65. PubMed ID: 21468954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Protocol for the Preparation of Cryoprecipitate and Cryo-depleted Plasma for Proteomic Studies.
    Sparrow RL; Simpson RJ; Greening DW
    Methods Mol Biol; 2017; 1619():23-30. PubMed ID: 28674874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of Cryoprecipitate and Cryo-depleted Plasma for Proteomic Research Analysis.
    Sparrow RL; Simpson RJ; Greening DW
    Methods Mol Biol; 2023; 2628():41-49. PubMed ID: 36781778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma.
    Caudill JS; Nichols WL; Plumhoff EA; Schulte SL; Winters JL; Gastineau DA; Rodriguez V
    Transfusion; 2009 Apr; 49(4):765-70. PubMed ID: 19192257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the products of cryoprecipitation: RiCoF is deficient in cryosupernatant plasma.
    Freedman M; Rock G
    Transfus Apher Sci; 2010 Oct; 43(2):179-82. PubMed ID: 20719565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
    Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC; Pepper DS; Griffin B
    Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of human thrombin for use in a fibrin glue.
    Rock G; Neurath D; Semple E; Harvey M; Freedman M
    Transfus Med; 2007 Jun; 17(3):187-91. PubMed ID: 17561860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple method for preparation of cryoprecipitate (CP) and cryodepleted plasma (CDP).
    Prohaska W; Kretschmer V
    Infusionsther Klin Ernahr; 1984 Dec; 11(6):342-4. PubMed ID: 6441780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of von Willebrand factor and factor VIII in canine cryoprecipitate under various conditions of storage.
    Stokol T; Parry BW
    Res Vet Sci; 1995 Sep; 59(2):152-5. PubMed ID: 8525105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
    Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
    Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
    Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
    Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of human factor VIII. III. Transitions between forms of factor VIII present in cryoprecipitate and in cryosupernatant plasma.
    Over J; Bouma BN; Sixma JJ; Bolhuis PA; Vlooswijk RA
    J Lab Clin Med; 1980 Mar; 95(3):323-34. PubMed ID: 7354239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryoprecipitate of intermediate purity produced in a closed thaw-siphon system from DDAVP stimulated blood donor plasma.
    Konecka G; Bykowska K; Ludwicka A; Letowska M; Wegrzynowicz Z; Sablinski J; Lopaciuk S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):565-70. PubMed ID: 1714861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical evaluation of cryoprecipitate for replacement of fibrinogen.
    Sørensen B; Bevan D
    Br J Haematol; 2010 Jun; 149(6):834-43. PubMed ID: 20456356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cryoprecipitate and plasma on plasma von Willebrand factor multimeters and bleeding time in Doberman Pinschers with type-I von Willebrand's disease.
    Ching YN; Meyers KM; Brassard JA; Wardrop KJ
    Am J Vet Res; 1994 Jan; 55(1):102-10. PubMed ID: 8141483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of coagulation factors in thawed, solvent/detergent-treated plasma during storage at 4 degrees C for 6 days.
    Buchta C; Felfernig M; Höcker P; Macher M; Körmöczi GF; Quehenberger P; Heinzl H; Knöbl P
    Vox Sang; 2004 Oct; 87(3):182-6. PubMed ID: 15569070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of factor VIII and von Willebrand factor activities during cold storage of whole blood is reversed by rewarming.
    Refaai MA; Van Cott EM; Lukoszyk M; Hughes J; Eby CS
    Lab Hematol; 2006; 12(2):99-102. PubMed ID: 16751138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in the fibrinogen and von Willebrand factor content of cryoprecipitate. Implications for reducing donor exposure.
    Hoffman M; Jenner P
    Am J Clin Pathol; 1990 May; 93(5):694-7. PubMed ID: 2327369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.